P/E at 33.19 vs Industry's 33.06: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Near-Industry P/E Reflects Balanced Market Sentiment

The current P/E of 33.19 for Sun Pharmaceutical Industries Ltd closely mirrors the Pharmaceuticals & Biotechnology sector average of 33.06. This negligible premium suggests that the market is pricing the stock in line with its peers, reflecting neither significant overvaluation nor discount. Such valuation alignment often indicates that investors are weighing the company’s fundamentals and sector outlook evenly. However, this equilibrium masks underlying performance divergences that merit closer examination — previously rated Buy, what is Sun Pharma’s current rating? The reassessment to Hold signals a more cautious stance amid evolving market dynamics.

Performance Across Timeframes: Divergent Momentum Signals

Examining the stock’s returns over multiple periods reveals a nuanced picture. Over the past year, Sun Pharmaceutical Industries Ltd has declined by 8.34%, underperforming the Sensex’s 2.97% loss. This underperformance contrasts sharply with the three-month window, where the stock gained 1.37% while the Sensex fell 5.04%. The year-to-date return of -3.82% also outpaces the broader market’s -9.14%, indicating some recovery in recent months despite longer-term weakness.

Shorter-term trends show the stock underperforming marginally today with a 1.54% decline versus the Sensex’s 0.30% drop, and a one-week loss of 1.27% compared to the Sensex’s 1.36% fall. The one-month return of -5.64% lags the Sensex’s positive 4.54%, highlighting recent volatility and mixed investor sentiment. This divergence between short and medium-term returns raises the question — is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Moving Average Configuration: Mixed Signals Amidst a Larger Downtrend

The technical setup for Sun Pharmaceutical Industries Ltd reveals a nuanced trend. The stock currently trades above its 5-day moving average but remains below the 20-day, 50-day, 100-day, and 200-day moving averages. This configuration suggests a short-term bounce within a broader downtrend, as the longer-term averages continue to exert resistance.

The recent two-day consecutive gain was reversed today with a 1.54% decline, indicating volatility and uncertainty in the near term. Such a pattern often reflects investor hesitation, where short-term optimism is tempered by longer-term caution. This technical picture raises the question — is this a recovery or a dead-cat bounce? The moving average configuration provides the clearest answer.

Sector Context: Pharmaceuticals & Biotechnology Showing Positive Result Trends

Within the Pharmaceuticals & Biotechnology sector, only one stock has declared results recently, which was positive. This limited data suggests a cautiously optimistic environment for the sector, with no flat or negative results reported so far. The sector’s average P/E of 33.06 aligns closely with Sun Pharmaceutical Industries Ltd’s valuation, reinforcing the notion that the company’s market pricing is consistent with sector fundamentals.

Rating Context: Previously Rated Buy, Now Reassessed

Sun Pharmaceutical Industries Ltd was previously rated Buy by MarketsMOJO but had its rating updated to Hold on 21 Apr 2026. This change reflects a reassessment of the company’s valuation and performance metrics amid shifting market conditions. The Mojo Score stands at 62.0, indicating a moderate outlook. The rating update invites investors to consider the implications carefully — should investors in Sun Pharma hold, buy more, or reconsider?

Market Capitalisation and Sector Positioning

With a market capitalisation of ₹3,96,850 crores, Sun Pharmaceutical Industries Ltd is firmly positioned as a large-cap stock within the Pharmaceuticals & Biotechnology sector. This scale provides it with significant market influence and resilience, although recent performance metrics indicate challenges in maintaining momentum relative to the broader market.

Long-Term Performance: Strong Gains Despite Recent Weakness

Over longer horizons, the stock has delivered robust returns. The three-year return stands at 68.90%, more than double the Sensex’s 28.93%. Over five years, the gain is an impressive 159.39%, compared to the Sensex’s 61.72%. However, the ten-year return of 101.67% trails the Sensex’s 199.67%, reflecting periods of relative underperformance in the distant past. These figures highlight the stock’s capacity for significant growth, tempered by cyclical fluctuations and sector-specific headwinds.

Intraday and Recent Trading Activity

On 24 Apr 2026, Sun Pharmaceutical Industries Ltd opened at ₹1,674.6 and traded at this level throughout the day, closing with a 1.54% decline. This performance slightly underperformed the sector by 0.28%. The stock’s fall after two consecutive days of gains suggests a pause or potential reversal in short-term momentum, consistent with the mixed moving average signals.

Conclusion: A Complex Data Story Demands Careful Analysis

The data for Sun Pharmaceutical Industries Ltd paints a multifaceted picture. Its valuation aligns closely with the sector, yet performance across timeframes diverges, with recent short-term gains contrasting longer-term declines. The moving average configuration indicates a tentative bounce within a broader downtrend, while sector results remain positive but limited in scope. The rating update from Buy to Hold reflects these complexities, urging investors to weigh the data carefully — what is the current rating for Sun Pharma?

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today